Supplementary Prospectus
A supplementary prospectus has been lodged with the Australian Securities and Investments Commission. This supplementary prospectus is intended to be read with the prospectus dates
A supplementary prospectus has been lodged with the Australian Securities and Investments Commission. This supplementary prospectus is intended to be read with the prospectus dates
Imagion Biosystems has today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 31 March 2020. Read the
Imagion Biosystems has announced receipt of its 2019 R&D tax incentive claim of A$2,197,028 from the Australian Tax Office (ATO). In May 2019 the Company
Imagion Biosystems Limited (ASX:IBX) is pleased to confirm that the rights the subject of the Company’s Renounceable Rights Issue announced on Wednesday, 25 March 2020,
Imagion Biosystems Limited has accepted the resignation of non-executive director Bronwyn Le Grice. Ms Le Grice’s resignation is effective March 31st, 2020. Read Imagion Biosystems
Imagion Biosystems Limited has released the Renounceable Rights Issue Prospectus: For a renounceable pro rata offer of 204,512,879 Shares at an issue price of $0.01
Imagion Biosystems Limited has released Appendix 3B — Renounceable Rights Issue. Read Appendix 3B.
Imagion Biosystems Limited has released “Pro-Rata Renounceable Rights Issue”. Highlight of this issue include: Funds to complete the manufacture of nanoparticle material and initiate a
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX
Imagion Biosystems Limited wishes to advise that its Australian registered office address has changed with immediate effect to: c/o K&L Gates, Level 25, 525 Collins Street,
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
We have temporarily suspended our nanoparticle operations. Please revisit us in the future. We apologize for the inconvenience. Any questions, please email: info@imagionbio.com Dismiss